Financial Reports: Lilly

Lilly

3Q Revenues: $5.0 billion (+2%)

3Q Earnings: $799.7 million (+60%)

YTD Revenue: $14.6 billion (+1%)

YTD Earnings: $1.9 billion (-2%)

Comments: Novartis Animal Health and recently launched Cyramza and Trulicity sales, were partially offset by the unfavorable effect of foreign exchange and the residual impact of the Cymbalta patent expiration. Humalog sales were flat at $709 million in the quarter. Cialis sales were also flat at $566.1 million. Alimta sales declined 13% to $628.5 million. Forteo sales were up 5% to $348.9 million. Humulin sales were down 6% to $316.7 million. Cymbalta sales dropped 34% to $242.9 million. Zyprexa sales were $237.9 million, down 8%. Cyramza sales were $111.4 million in the quarter, and Trulicity sales were $73.7 million. In the quarter, the FDA approved Synjardy (empagliflozin and metformin hydrochloride) tablets and was launched for the treatment of type 2 diabetes. Animal health sales were $778.8 million up 33% driven by Novartis Animal Healthacquisition.